The present investigation examined the effect of interleukin-1␤ (IL-1␤) on progesterone production by human luteal cells and the expression and localization of the IL-1 system in the human corpus luteum (CL). Luteal cells were isolated from corpora lutea collected throughout the luteal phase. After dispersion, luteal cells were treated with a panel of monoclonal antibodies directed to leukocytespecific molecules. The leukocytes were isolated with immunomagnetic beads. Leukocyte-free luteal cells exhibited greater steroidogenic responsiveness to hCG toward the end of the luteal phase. The treatment of mixed luteal cells (total luteal cells) with IL-1␤ inhibited by 60% hCG-stimulated progesterone production. Interestingly, the treatment of leukocyte-free luteal cells with IL-1␤ did not affect progesterone production. In addition, the treatment of mixed luteal cells with monoclonal antibodies against IL-1 receptor type I (IL-1RtI) resulted in a 2.5-fold increase in the hCG-supported progesterone production. IL-1RtI and IL-1 receptor antagonist were localized by immunohistochemistry in both somatic and immune cells of the CL. Flow cytometric analysis indicated that both nonleukocyte luteal cells and leukocyte-luteal cells exhibited IL-1Rt-I positive cells, representing 56% and 31% of the total luteal cells, respectively. However, 13% of nonleukocyte luteal cells did not express IL-1Rt-I. Northern analysis demonstrated the presence of the 5.1-kb IL-1RtI messenger ribonucleic acid transcript in CL of different ages. RT-PCR indicated that both leukocyte-free luteal cells and luteal leukocytes express IL-1RtI messenger ribonucleic acid. We conclude that 1) luteal leukocytes have an inhibitory effect on hCG-stimulated progesterone production; 2) Il-1␤ inhibits hCG-stimulated progesterone production only in mixed luteal cell cultures, indicating that leukocytes mediate the effect; 3) the somatic and immune cells of the CL are sites of action and expression of the IL-1 system; and 4) interaction between the steroidogenic and immune cells of the CL suggests a functional intraovarian role for IL-1␤ in CL physiology. (J Clin Endocrinol Metab 84: 4239 -4245, 1999) T HE HUMAN corpus luteum (CL) undergoes remarkable changes in structure and function from the time of ovulation to its regression in a non-fertile cycle. During its functional life the CL secretes the steroid hormone that are essential for maintenance of the secretory endometrium, implantation, and sustaining early pregnancy. Luteinization of the ovulatory follicle and steroidogenesis are dependent on pituitary-derived LH acting through a cAMP signaling cascade. Within luteal tissue, the steroidogenic actions of LH are modulated by a variety of hormones, growth factors, and cytokines, including interleukin-1␤ (IL-1␤), IL-1␣, and tumor necrosis factor-␣ (TNF␣) (1). These polypeptides are essential to the immune cascade and stimulate or inhibit cell growth depending on their concentrations and target cells. IL-1␤ is known to inhibit luteinization of cultured murine and porcine granulosa cells (2, 3). Furthermore, IL-1␤ inhibited hCG stimulated-progesterone production by human granulosa cells cocultured with white blood cells (4). It is thought that IL-1␤ exerts its action through cell surface receptors. To date two IL-1 receptors (types I and II) have been identified. In the human, the type I receptor (IL-1RtI) possesses a 213-amino acid long intracytoplasmic domain, whereas the type II receptor has a short 29-residue intracytoplasmic domain (5). Current information indicates that IL-1␤ signaling occurs exclusively via IL-1RtI (6). Cells regulated by IL-1␤ also produce a IL-1 receptor antagonist (IL-1Ra). The complete IL-1␤ system including genes encoding IL-1␤, IL-1RtI, and IL-IRa have been detected in the ovary of several species, including the human (7).
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Interestingly, cultured human granulosa and thecal cells did not express messenger ribonucleic acid (mRNA) for IL-1␤ under basal conditions, but they did express mRNA for IL-1RtI (7) . Treatment of ovarian cell cultures with forskolin induced IL-1␤ transcripts, but only in granulosa cells. In addition, IL-1-like activity has been detected in human follicular fluid, and the IL-1␤ transcript is more abundant in cells of follicular aspirates than IL-1␣. An intermediary role for IL-1 in the ovulatory process has been postulated (5).
The cells comprising the CL have distinct morphological, endocrine, and biochemical properties. Cells present in the CL include small and large luteal cells, fibroblasts, and endothelial and immune cells. These cells change in number, morphology, function, and secretory capability throughout the life span of the CL (8, 9) . Cells derived from the CL produce IL-1␤ in culture, particularly immune cells (10) . However, there is limited information regarding the role of IL-1␤ and the cell localization of the IL-I system in the human CL. In the present investigation we examined the ability of IL-1␤ to modulate basal and hCG-stimulated progesterone production by human luteal cells. Furthermore, studies were carried out to elucidate the types of luteal cells that express IL-1RtI and IL-1Ra in the human CL.
Materials and Methods
All chemicals, culture media, and hormones were obtained from Sigma Chemical Co. 
Antibodies
The following mouse monoclonal antibodies (mAb) were gifts from Dr. Maria Rosa Bono (Faculty of Sciences, University of Chile, Santiago, Chile): mAb W6/32 (IgG2a antihuman major histocompatibility complex class I) and mAb GAP8.3 (IgG2a anti-CD45). Dr. Francisco Sánchez-Madrid (The Princess Hospital, Madrid, Spain) provided mAb Bear-I (IgG1 anti-CD 11b) and mAb LIA 3/2 (IgG1 anti-CD 18). Mouse mAb Tuk4 (IgG1 anti-CD14) was purchased from (DAKO Corp., Carpenteria, CA), the labeled F(abЈ) 2 antibody (antimouse IgG) was obtained from Immunotech (Marseille, France), the mouse mAb (antihuman IL-1RtI) was purchased from Genzyme Transgenics Corp. (Cambridge, MA), and rat mAb 4 C1 (IgC2a antihuman IL-1RtI) was obtained from PharMingen (San Diego, CA).
Patients and tissues
CL were obtained from 16 eumenorrheic women, aged 27-38 yr, undergoing laparotomy for tubal sterilization (n ϭ 10) or myomas (n ϭ 6). at the San Borja Arriarán Clinical Hospital, University of Chile, National Health Service (Santiago, Chile). None of the patients had experience infertility or endometriosis and had stopped any hormonal contraception at least 3 months before surgery. The study was approved by the institutional review board of the University of Chile. All patients gave their informed consent for removal of the CL.
After lutectomy, the tissue was transported to the laboratory in sterile saline. The cycle date of each woman was confirmed by endometrial biopsy (11) and classified as early (1-4 days; n ϭ 5), mid (5-9 days; n ϭ 6), or late (10 -14 days; n ϭ 5). One piece of each CL was placed in 10% formalin for histological examination (12) .
Cell dispersion
Luteal cells were dispersed as previously described (13) . Briefly, CL were enzymatically dissociated in culture medium 199/HEPES (25 mmol/L) containing NaHCO 3 (26 nmol/L), penicillin (50 IU/mL), collagenase trypsin-free (740 IU/100 mg tissue), and deoxyribonuclease (14 kallikrein inhibitor units/100 mg tissue). After 90 min, luteal cells were washed once with culture medium and twice with Dulbecco's Ca 2ϩ -and Mg 2ϩ -free phosphate-buffered saline (PBS) containing ethylenediamine tetraacetate (1 mmol/L). Red blood cells were removed by Histopaque column (density, 1.007). The cell viability was more than 90%, as assessed by the trypan blue exclusion method.
Luteal leukocyte isolation
After luteal dispersion, a fraction of luteal cells was incubated with a panel of mouse mAbs (GAP 8.3, Bear-1, and LIA 3/2) directed to leukocyte-specific molecules as previously described (10) . Leukocytes were separated from luteal cells in a magnetic concentrator (DynAl, Chantilly, VA). Subsequent to isolation of luteal leukocytes, the cell viability of luteal cells was greater than 90%, as determined by the trypan exclusion method.
Cell culture
Luteal cells were cultured as previously described (13, 14) . Briefly, mixed luteal cells (total luteal cells) and leukocyte-free luteal cells (0.5-1 x10 5 /well) were cultured in serum-free medium and treated with IL-1␤ (25 ng/mL) in the absence and presence of hCG (10 IU/mL), for 24 h. To test the specificity of IL-1␤, some cells were treated with anti IL-1RtI mAb in the presence and absence of hCG. Culture medium was collected for determination of progesterone concentrations.
Human granulosa cells were isolated from patients undergoing in vitro fertilization/embryo transfer. The cells were cultured as previously described (19) and used to detect IL-1RtI by indirect immunofluorescence.
Detection of IL-1RtI by flow cytometry
To investigate the protein expression of IL-1RtI on mixed luteal cells, flow cytometric analysis was performed as described previously with minor modifications (10) . Briefly, dual color immunofluorescence staining was performed to discriminate the expression level of IL-1RtI on luteal leukocytes and leukocyte-free luteal cells. In the first step, suspensions of mixed luteal cells were simultaneously incubated for double staining with the rat mAb 4C1 (anti IL-1RtI) and the panel of mouse antileukocyte mAbs for 40 min at 4 C, and then washed in PBS. The second step included incubation with biotin-conjugated goat antirat Ig polyclonal antibody for 30 min at 4 C, followed by two washes. In the third step, the cells were incubated with the conjugate streptavidinphycoerythrin and fluorescein-F(ab) 2 anti-mouse Ig for 30 min at 4 C. After two washes, the cells were resuspended at a concentration of 0.6 ϫ 10 6 /mL in PBS and immediately analyzed or stored overnight in PBS containing 0.5% formaldehyde in the dark until analysis. Control samples included assessment of autofluorescence and negative controls (absence of primary mAbs and/or secondary mAbs). No cross-reaction was observed between secondary antibodies, indicating highly specific binding of the mouse or rat Ig.
RNA isolation and Northern analysis
The presence of IL-1RtI mRNA was determined in CL collected throughout the luteal phase. Corpora lutea were kept frozen at Ϫ70 C. Total RNA was prepared as described by Chromczynski and Sacchi (15) and was quantified by absorbance at 260 nm. Northern analysis was carried out using Il-1RtI complementary DNA (cDNA) as a probe (Immunex Corp., Seattle, WA). Briefly, 15 g total RNA were resolved on a 1% formaldehyde-agarose gel, blotted onto a nylon membrane (Schleicher & Schuell, Inc., Nytran), and cross-linked by UV irradiation. The membranes were prehybridized for 1 h at 65 C in a solution containing 0.5 mol/L NaH 2 PO 4 (pH 7), 0.1 mmol/L ethylenediamine tetraacetate, 0.5% BSA, and 7% SDS. Hybridization was carried out overnight at 65 C in the same solution after the addition of the 32 P-labeled probe (10 6 cpm/mL solution). Membranes were washed in 2 ϫ SSC (standard saline citrate)-0.1% SDS for 30 min at room temperature, followed by two washes in 0.1 ϫ SSC-0.1% SDS for 30 min at 60 C. Blots were exposed to x-ray film (reflection NEF-496, DuPont/NEN, Boston, MA), for 72 h.
RT-PCR
The presence of IL-1RtI transcripts in mixed luteal cells and leukocyte-free luteal cells was determined by RT-PCR. Oligonucleotide primers were designed according to previously published sequences of IL1RtI and IL-1Ra, predicting PCR products of 441 and 511 bp, respectively (16, 17) . Primer sequences were as follows: IL-1Rt1: forward, 5Ј-GCC AAG AGT TCT TTA GGT GCC-3Ј; reverse, 5Ј-CTC ACT GCA ACC TCC GTC TC-3Ј; and IL-1Ra: forward, 5Ј-CAG AAG ACC TCC TGT CCT ATG AGG-3Ј; reverse, 5Ј-GAT GAG CAG GAG GAC CTT CAT-3Ј. Total RNA (5 g) was reverse transcribed in a 20-L reaction containing 10 mol/L reverse primer, AmpliTaq buffer, 0.2 mmol/L of each deoxy-NTP, 200 U reverse transcriptase (Superscript II, Life Technologies, Inc., Gaithersburg, MD), and 5 U RNasin (Promega Corp., Madison, WI) at 42 C for 60 min. The PCR amplifications were performed by adding 10 mol/L forward primer, Taq buffer, 0.2 mmol/L of each deoxy-NTP, and 1 U Taq DNA polymerase (Promega Corp.) to the previous reaction mixture in a final volume of 50 L. The cycling conditions for IL-1RtI were as follows: initial denaturation at 95 C for 5 min, followed by 30 cycles of denaturation at 95 C for 1 min, annealing at 58 C for 1 min, extension at 72 C for 1 min, and a final extension at 72 C for 10 min. Cycling conditions for IL-1Ra were the same, except for the annealing temperature, which was 55 C. Control reactions without cDNA were carried out in parallel and resulted in negative determination. PCR products were analyzed by electrophoresis in 1.25% agarose gel. Purified PCR products were sequenced using the DNA ds Cycle Sequencing System (Life Technologies, Inc.).
Nested PCR for IL-1Ra
IL-1Ra product obtained from RT-PCR was submitted to a second PCR amplification (nested), using the following specific primers: forward, 5Ј-CAG AAG ACC TCC TGT CCT ATG AGG-3Ј; and reverse, 5Ј-GAT GAG CAG GAG GAC CTT CAT-3Ј. Cycling conditions were the same as described for the first PCR reaction, except for the annealing temperature, which was 60 C. Purified PCR products were sequenced using the DNA ds Cycle Sequencing System (Life Technologies, Inc.).
Immunohistochemical staining procedures
CL were formalin-fixed and paraffin embedded. Five-micron sections were processed for routine hematoxylin-eosin staining and immunohistochemistry as previously described (18) . Briefly, the slides were deparaffinized in xylene, followed by rapid rehydration through a graded series of alcohols. For the avidin-biotin-peroxidase method, endogenous peroxidases were blocked with 1% H 2 O 2 in 96% methanol. Nonspecific binding was blocked with horse serum followed by incubation with the primary antibodies: monoclonal mouse antihuman IL1RtI and Il-1Ra antibody, respectively (Genzyme Corp., Cambridge, MA). Control incubations included deletion of the primary antibody. After rinsing with PBS, sections were incubated with a secondary IgG antibody. Immunoreaction products were visualized by incubating sections with 3Ј-diaminobenzidine tetrahydrochloride as substrate solution.
Indirect immunofluorescence procedures for lutein and granulosa lutein cells
Lutein or luteinized granulosa cells grown on coverslips were washed twice in prewarmed (37 C) DMEM and twice in prewarmed PBS containing 1.5 mmol/L Ca 2ϩ and fixed in 100% methanol (Ϫ20 C for 5 min). Cells were incubated in 10% normal goat serum for 30 min at room temperature and then with 10 g/mL of the primary antibodies for 2 h at room temperature (18, 19) . A fluorescein-conjugated goat antimouse secondary antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) was used at a 1:200 dilution (30 min at room temperature). Coverslips were mounted on glass slides with Fluoromount G (Fisher Scientific, Malvern, PA) containing 1,4-diazabicyclo-(2,2,2)octane (DABCO, Polysciences, Inc., Warrington, PA) to stabilize fluorescence and were photographed with a Nikon microscope (Melville, NY).
Data analysis
All experiments were conducted in duplicate and repeated at least three times. Experimental data are presented as the mean Ϯ se. The percent increment in progesterone production was analyzed by twotailed Student's t test for comparison between control and treated conditions and between different luteal cell populations. P Ͻ 0.05 was considered statistically significant. Figure 1 illustrates the effect of hCG (10 IU/mL) on progesterone accumulation by cultured mixed luteal cells and leukocyte-free luteal cells. The time course of hCG stimulated-progesterone accumulation was examined in luteal cells of different ages. Culture medium from mid and late leukocyte-free luteal cells displayed higher progesterone accumulation compared with that from mixed luteal cells, respectively (P Ͻ 0.05). No difference was noted in the progesterone accumulation by mixed luteal and leukocyte-free luteal cells from early CL. These data suggest a luteal agedependent interaction among cAMP signaling, luteal steroidogenic cells, and luteal leukocytes. Figure 2 depicts the effect of IL-1␤ (25 ng/mL) in the presence and absence of hCG on progesterone accumulation by mixed and leukocyte-free early luteal cells. IL-1␤ had no effect on basal progesterone production by either mixed luteal cells or leukocyte-free luteal cells. In contrast, treatment with IL-1␤ inhibited hCG-stimulated progesterone accumulation in mixed luteal cells by 60%,(P Ͻ 0.05), but did not affect leukocyte-free luteal cells. This finding suggests that the action of IL-1␤ is leukocyte mediated. To verify the specific effect of IL-1␤ on luteal steroidogenesis, the neutralizing 4C1 mAb directed to IL-1RtI was added to the mixed mid luteal cells (8 g ϫ 10 5 cells) for 24 h. Fig. 3 illustrates that hCG-stimulated progesterone accumulation by mixed luteal cells was amplified 2-fold in the presence of IL-1RtI mAb compared with that in the presence of hCG alone (P Ͻ 0.05). Treatment with IL-1RtI mAb had no effect on basal progesterone accumulation or hCG-stimulated progesterone accumulation in leukocyte-free luteal cells (data not shown). These findings suggest that the action of IL-1␤ on steroidogenesis is mediated by the leukocyte IL-1RtI. Figure 4 , the upper panel shows the immunohistochemical identification of IL-1RtI in CL collected during the midluteal phase. Immunostaining was localized in the cytoplasmic plasma membrane of luteal cells (Fig. 4A) . In control experiments, no immunostaining was noted when primary antibody was omitted (Fig. 4B ). The middle panel shows luteinized granulosa cells in primary culture (Fig. 4C , immunofluorescence; Fig. 4D , phase contrast). The cells displayed numerous cell to cell contacts, and the cell morphology is consistent with steroidogenic cells. The IL-1RtI protein was visualized in leukocyte-free granulosa lutein cells by indirect immunofluorescence. These cells exhibited intense staining for IL1RtI. However, we noticed that some of these cells did not stain for IL-1RtI, suggesting that IL-1RtI is not constitutively present in all granulosa-lutein cells. The lower panel shows the indirect immunofluorescence for IL-1RtI in luteal cells. Mixed luteal cells (Fig. 4E) as well as leukocyte-free luteal cells (Fig. 4F ) displayed intense staining for IL-1RtI. The negative control included the omission of the primary antibody and showed no staining (Fig. 4G) .
Results

IL-1RtI gene expression in the corpus luteum
To determine whether the CL is a site of IL-1RtI gene expression during the luteal phase, Northern blot was performed using IL-1RtI cDNA as a probe. Figure 5 is an autoradiogram that illustrates the presence of the IL-1RtI mRNA transcript in CL (total tissue) of different stages. The cDNA probes yield a major band of 5.1 kb in the different stages of the CL. Secretory endometrium was used as a positive control. These data indicate that IL-1RtI mRNA is expressed during all stages of the luteal phase. , ϫ400) . B, Control section from mid-CL (magnification, ϫ100). C, Indirect immunofluorescence identified the IL-1RtI in human luteinized granulosa cells in primary culture (magnification, ϫ400). D, Phase contrast microscopy of human granulosa cells in primary culture (magnification, ϫ400). E and F, Indirect immunofluorescence of midluteal mixed and leukocyte-free luteal cells, respectively (magnification, ϫ400). G, Control mixed luteal cells (magnification, ϫ100). 
IL-1RtI in luteal leukocytes and in nonleukocyte luteal cells
RT-PCR was used to determine whether IL-1RtI is expressed in both luteal leukocytes and nonleukocyte luteal cells. Figure 6 depicts a 441-bp PCR product corresponding to the expected size of IL-1RtI mRNA and was found in mixed luteal cells, leukocyte-free luteal cells, and luteal leukocytes. All products obtained were sequenced, confirming individual product identity. Secretory endometrial cell RNA was used as a positive control, and peripheral leukocytes that do not express the IL-RtI mRNA were used as a negative control. In all experiments ␤-actin was used as a control for sample to sample variation. Figure 7 shows the immunohistochemical identification of IL-1Ra from CL collected during the midluteal phase. The immunostaining was localized in the cytoplasmic membrane of luteal cells (Fig. 7A) . In control experiments, no immunostaining was noted when primary antibody was omitted (Fig. 7B ). The lower panel shows the indirect immunofluorescence for IL-1Ra in luteal cells. Mixed luteal cells (Fig. 7C) as well as leukocyte-free luteal cells (Fig. 7D ) displayed intense staining for IL-1Ra. The negative control included the omission of the primary antibody and shows no staining (Fig.  7E) . Figure 8 illustrates the RT nested-PCR of IL-1Ra mRNA in mixed luteal cells. A 551-bp PCR product corresponding to the expected size of IL-1Ra mRNA was found in mixed luteal cells. The product obtained was sequenced, confirming product identity.
Immunohistochemical identification and mRNA expression of IL-1Ra in the CL
Flow cytometric analysis
We have previously validated by flow cytometry the purity of the leukocyte-free luteal cell population as greater than 99% (10) . In this study, flow cytometric analysis assessed the level and cellular distribution of IL-1RtI in the CL. 
Discussion
Several studies have suggested a role for intraovarian IL-1␤ in the ovulatory process and in subsequent formation of the CL. IL-1␤ is a polypeptide predominately produced and secreted by activated macrophages. Previous work conducted in our laboratory established that luteal leukocytes diminish the ability of midluteal cells to produce progesterone (10) . The present study tested the concept that IL-1␤ is a modulator of hCG-stimulated progesterone production by luteal cells of different ages in the presence and absence of luteal leukocytes.
The pattern of hCG-stimulated progesterone secretion by mixed luteal cells throughout the luteal phase is consistent with previous findings, indicating a progressive decline toward the end of the luteal phase (13) . Interestingly, leukocyte-free luteal cells exhibited a greater responsiveness to hCG in term of progesterone secretion, particularly during the late luteal phase. This finding suggests a leukocyte inhibitory effect on hCG-stimulated progesterone production. Consistent with this observation, IL-1␤ was able to inhibit hCG-stimulated progesterone production only in mixed luteal cells, indicating a leukocyte-mediating effect.
On the other hand, IL-1␤ failed to modify basal progesterone production by mixed or leukocyte-free luteal cells, suggesting that IL-1␤ does not exert a direct effect on luteal steroidogenesis. These results point to a leukocyte-produced or released factor(s) that subsequently affects hCG-stimulated progesterone synthesis.
In contrast to its effect during the mid-and late luteal phase, hCG-stimulated progesterone production was similar in both early mixed luteal cells and leukocyte-free luteal cells. The lack of effect of early luteal leukocytes on hCG-stimulated progesterone production is interesting, possibly suggesting that the population or function of luteal leukocytes changes during the luteal phase or that the sensitivity of luteal cells to the leukocyte-derived factor change. The fact that blood lymphocytes represent the predominant subtypes of leukocytes in early CL might explain the lack of effect on luteal steroidogenesis (20) . In the monkey, IL-1␤ stimulates PGF 2␣ production by luteal cells isolated only during the mid and late luteal phase (21) . Interestingly, in cultured human granulosa cells IL-1␤ increases cyclooxygenase-2 mRNA levels, which represents the rate-limiting enzyme in conversion of arachidonic acid to prostanoids. In addition, IL-1␤ up-regulated the receptor for PGF 2␣ (22) . PGF 2␣ inhibits adenyl cyclase activity in luteal cells (1) . Our finding that treatment with IL-1␤ inhibited by 60% the hCG-stimulated progesterone production by mixed early luteal cells and was without effect on leukocyte-free luteal cells highlights the importance of both luteal leukocytes and IL-1␤ in the modulation of progesterone production and suggests that PGF 2␣ could drive the inhibitory action of IL-1␤ in luteal cells steroidogenesis.
To understand the specific action of IL-1␤ on luteal steroidogenesis, we examined in vitro the effect of a neutralizing mAb directed to IL-1RtI on basal and hCG-stimulated progesterone production. The treatment resulted in a 2.5-fold increase in the hCG-supported progesterone production, but it was without effect on basal steroidogenesis. The underlying mechanism controlling the antigonadotropic activity of IL-1␤ in luteal cells cannot be determined from this study, but several possible scenarios can be suggested. It has been recently noted that IL-1␤ favors the production/release of PGF 2␣ and nitric oxide by luteal tissue (21) (22) (23) (24) . Both, PGF 2␣ and nitric oxide inhibit progesterone synthesis at the level of adenyl cyclase activity and cytochrome P450ssc, respec- tively. These findings are consistent with the recent report by Bréard et al., who found that IL-1␤ diminished hCG-stimulated cAMP generation in rabbit granulosa cells (25) . Collectively, these data support the idea of a functional role for IL-1␤ in human CL regression.
The second part of our study was designed to assess the mRNA expression and cellular localization of IL-1RtI and IL-1Ra within the CL. Immunoreactive IL-1RtI, and gene expression (mRNA) were localized in both somatic cells and immune cells of the gland. This is consistent with our flow cytometric assessment that detected IL-1RtI protein in both cell types. In addition, our data indicate that 56% of cells that stain positively for IL-1RtI are nonimmunological luteal cells. These results are in agreement with those of Piquette et al. (26) , who reported that human granulosa-lutein cells collected at the time of oocyte retrieval, and not macrophages, account for the majority of the immunohistochemical staining for IL-1RtI.
Northern blot analysis documented the presence of single mRNA transcript for IL-1RtI (5.1 kb) in the CL. Furthermore, this mRNA transcript is present in CL of different ages. Cellular localization of a fragment of the IL-1RtI transcript was performed by RT-PCR. The 441-bp RT-PCR product corresponded to the amplified IL-1RtI fragment and is localized in leukocyte-free luteal cells and luteal leukocytes. These data indicate that the CL is a site of IL-1RtI gene expression and IL-1␤ action.
IL-1 exerts its action through cell surface receptors. A naturally occurring antagonist, IL-1Ra, is also produced by the cells to modulate the actions of IL-1, preventing postreceptor activation (20) . Our observations documented the presence of immunoreactive IL-1Ra in histological section of the CL throughout the luteal phase. Furthermore, immunofluorescence procedures identified IL-1Ra in luteal leukocytes and leukocyte-free luteal cells. The IL-1Ra mRNA was only examined in mixed luteal cells. We have previously shown the ability of human luteal cells to produce IL-1␤ (9) . Taken together these findings indicate the presence of a complete intraluteal IL-1 system in the CL, replete with ligand, receptor, and receptor antagonist.
In summary, this study demonstrated localization of the IL-1 system in both immune and somatic cells of the human CL. In addition, our findings reveal a functional role for IL-1␤ in the regulation of luteal steroidogenesis in vitro. The factor(s) that mediates the antigonadotropic action of IL-1␤ on hCG-stimulated progesterone secretion is mainly leukocyte dependent. The lack of effect of IL-1␤ on progesterone synthesis in leukocyte-free luteal cells suggests a nonsteroidogenic role for IL-1RtI localized in somatic luteal cells.
Finally, these findings highlight the importance of resident macrophages in the regulation of CL development, function, and regression and suggest an interaction between the immune and steroidogenic cells within the corpus luteum.
